News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
37–66
Matches
66
Sources here
17
Companies here
1
Search results Stored financial headlines

Active search

66 matching headlines

Ticker or company: OTLKMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

finance.yahoo.com Guidance Main company 🇺🇸 United States

Outlook Therapeutics Targets Multibillion Dollar Ophthalmology Market With New Drug After FDA Rejection

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. On Friday, the U.S. Food and Drug Administration (FDA) approved Outlook Therapeutics Inc.'s ONS-5010/LYTENAVA (bevacizumab-vikg, bevacizumab gamma) for neovascular age-related macular degeneration (nAMD), commonly known as wet …

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Earnings Main company 🇺🇸 United States

Outlook Therapeutics, Inc. (NASDAQ:OTLK): When Will It Breakeven?

This article examines when Outlook Therapeutics, Inc. (NASDAQ:OTLK) is expected to achieve breakeven profitability. It analyzes the company's financial performance and projections to forecast its path to profitability. The analysis helps investors understand the timeline for OTLK to become financially self-sufficient.

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stocktwits Earnings Main company 🇺🇸 United States

Outlook Therapeutics’ Recently Approved Therapy Could Become Preferred Anti-VEGF Treatment Option In $8.5B US Retina Market, Says BTIG

BTIG upgraded Outlook Therapeutics to 'Buy' with a $4 price target after the FDA approved its wet AMD therapy, Lytenava, positioning it as a potential preferred anti-VEGF treatment in the $8.5 billion U.S. retina market. Despite previous regulatory setbacks and competition from lower-cost alternatives, …

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Market source Earnings Main company 🇺🇸 United States

Outlook Therapeutics shares climb after FDA clears LYTENAVA for wet AMD

Outlook Therapeutics (NASDAQ:OTLK) shares surged after the FDA approved LYTENAVA for wet AMD, making it the first and only FDA-approved ophthalmic formulation of bevacizumab for this condition. The positive momentum was further bolstered by a BTIG analyst upgrade from Neutral to Buy with a …

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Analyst action Main company 🇺🇸 United States

BTIG upgrades Outlook Therapeutics stock rating on FDA approval

BTIG upgraded Outlook Therapeutics (NASDAQ:OTLK) to Buy with a $4.00 price target after the FDA approved its drug LYTENAVA for wet age-related macular degeneration. The stock saw a significant increase, though InvestingPro analysis suggests it's slightly overvalued. The company is now focusing on the …

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

OTLK Stock Jumps Overnight After FDA Approval Of Wet AMD Drug — Analysts See Nearly 300% Upside

Outlook Therapeutics (OTLK) saw its stock jump after receiving FDA approval for Lytenava, its wet AMD drug. This approval, which came ahead of schedule and follows previous regulatory setbacks, positions Lytenava as the first FDA-approved bevacizumab formulation specifically for ophthalmic use. Analysts are projecting …

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
nasdaq.com Guidance Main company 🇺🇸 United States

Outlook Therapeutics Wins FDA Nod For LYTENAVA After Three Setbacks

(RTTNews) - Outlook Therapeutics (OTLK) announced that the FDA has approved LYTENAVA as the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of neovascular age-related macular degeneration (wet AMD). Wet AMD is a leading cause of vision loss in older adults, …

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TechStock² Earnings Main company 🇺🇸 United States

Outlook Therapeutics (NASDAQ:OTLK) suspended post-Lytenava approval, with funding under pressure from looming warrants

Outlook Therapeutics (NASDAQ:OTLK) shares were suspended from trading following the FDA approval of its drug Lytenava for wet age-related macular degeneration. While the approval resolves a major regulatory hurdle, the company now faces financial pressures from looming warrant exercises and the need for significant …

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Reuters Guidance Main company 🇺🇸 United States

US FDA approves Outlook Therapeutics' eye disease drug

Outlook Therapeutics has received FDA approval for Lytenava, a drug designed to treat wet age-related macular degeneration (AMD), a leading cause of blindness in older adults. This marks the company's first entry into the U.S. market, with Lytenava specifically formulated for intravitreal administration, differentiating …

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
StocksToTrade Earnings Main company 🇺🇸 United States

OTLK Stock Slips After Regaining Nasdaq Compliance

Outlook Therapeutics Inc. (OTLK) regained Nasdaq compliance by maintaining a closing price above $1 for ten consecutive days, removing an immediate delisting threat. Despite this, the stock slipped roughly 3.5% on the day the news broke, indicating that traders view the compliance more as …

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
seekingalpha.com Guidance Main company 🇺🇸 United States

Outlook gains approval for ophthalmic bevacizumab for wet AMD

[AMD Abbreviation or acronym of age-related macular degeneration - eye problem in older persons. Word AMD is on foreground near eye model with stethoscope and visual acuity test on blurry background] Shidlovski * The US FDA has approved Outlook Therapeutics' (OTLK [https://seekingalpha.com/symbol/OTLK]) Lytenava (bevacizumab-vikg) …

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Guidance Main company 🇺🇸 United States

Outlook Therapeutics receives FDA approval for wet AMD treatment

Outlook Therapeutics Inc. (NASDAQ:OTLK) has received FDA approval for LYTENAVA (bevacizumab-vikg), its treatment for neovascular age-related macular degeneration (wet AMD). This marks the first FDA-approved ophthalmic formulation of bevacizumab for wet AMD, offering 12 years of market exclusivity. The company expects to make LYTENAVA …

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Outlook Therapeutics, Inc. Revenue Breakdown – SWB:41O

Outlook Therapeutics, Inc. (SWB:41O) reported a significant decrease in revenue, generating 1.20 million EUR last year, down from 7.47 million EUR the previous year. The Ophthalmic Formulation segment was the sole contributor to this revenue, and all revenue originated from the United States.

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Guidance Main company 🇺🇸 United States

Outlook Therapeutics grants options to CEO Robert C. Jahr and CFO Lawrence A. Kenyon

Outlook Therapeutics has granted stock options to its CEO, Robert C. Jahr, and CFO, Lawrence A. Kenyon, along with approving performance-linked cash bonuses. These awards are tied to the FDA approval of ONS-5010 and recognize their efforts in advancing the BLA through FDA review …

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Guidance Main company 🇺🇸 United States

OTLK|Outlook Therapeutics Inc|Price:0.756|Chg%:-0.132

This article provides a comprehensive financial overview of Outlook Therapeutics Inc (OTLK), a biopharmaceutical company specializing in ophthalmic formulations. It highlights the company's relatively stable fundamentals, high growth potential, and a "Buy" rating from analysts with a target price of $5.50. Despite a recent …

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Guidance Main company 🇺🇸 United States

OTLK|Outlook Therapeutics Inc|Price:1.305|Chg%:-0.035

This article provides a comprehensive financial overview of Outlook Therapeutics Inc (OTLK), a biopharmaceutical company specializing in ophthalmic formulations. It highlights the company's relatively stable fundamentals, high growth potential, and a "Buy" rating from analysts with a target price of $5.50. Despite a recent …

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Guidance Main company 🇺🇸 United States

Outlook Therapeutics (OTLK) CEO granted 100,000 stock options

Outlook Therapeutics, Inc. (OTLK) CEO Robert Charles Jahr was granted 100,000 stock options at an exercise price of $1.4304 per share under the company's 2024 Equity Incentive Plan. These options, granted on July 21, 2026, will vest fully on July 21, 2027, and expire …

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Guidance Main company 🇺🇸 United States

Outlook Therapeutics (NASDAQ: OTLK) grants 210,078 stock options to CFO

Outlook Therapeutics, Inc. reported that its Chief Financial Officer, Lawrence A. Kenyon, was granted 210,078 stock options on July 21, 2026. These options, under the company's 2024 Equity Incentive Plan, have an exercise price of $1.4304 per share, vest completely on July 21, 2027, …

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
www.timothysykes.com Earnings Main company 🇺🇸 United States

Outlook Therapeutics Inc. (OTLK) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live quotes and charts for Outlook Therapeutics Inc. (OTLK) stock on NASDAQ, showing its current price and daily performance. It also includes sections for analyst ratings and earnings information, though specific data for OTLK's earnings and analyst targets is currently unavailable. …

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
StocksToTrade Earnings Main company 🇺🇸 United States

OTLK Stock Slips As Warrant Resale Overhang Builds

Outlook Therapeutics Inc. (OTLK) stock recently slipped by 7.75% due to investor concerns over its FDA regulatory outcome and a significant warrant resale overhang. The company registered approximately 17.3 million shares tied to warrants and 17.26 million common shares for potential resale by existing …

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

Outlook Therapeutics, Inc. SEC Filing (Jul 22, 2026)

This article reports on an SEC Filing (Form EFFECT) by Outlook Therapeutics, Inc. (OTLK) dated July 22, 2026, which is categorized as having a neutral impact and sentiment. The filing indicates an effectiveness date of July 21, 2026, for an S-3 form. The article …

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Guidance Main company 🇺🇸 United States

Outlook Therapeutics Company Profile & Introduction

This document provides a company profile and introduction for Outlook Therapeutics. The article serves as a foundational overview of the company, likely detailing its operations, mission, and position within its industry.

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
The Globe and Mail Analyst action Main company 🇺🇸 United States

Outlook Therapeutics Shareholders Approve Major Capital Changes

Outlook Therapeutics shareholders have approved significant changes to the company's capital structure, including an increase in authorized common shares to 600 million and the authorization for a reverse stock split. These moves aim to provide financial flexibility for strategic initiatives, manage share price, and …

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Nigeria Guidance Main company 🇺🇸 United States

Form S-3 OUTLOOK THERAPEUTICS INC For: 17 July By Investing.com

This article announces that OUTLOOK THERAPEUTICS INC filed a Form S-3 on July 17. The filing is brief and primarily serves as a news item about the regulatory document, without providing further details on the content or implications of the S-3 filing itself. The …

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Guidance Main company 🇺🇸 United States

Outlook Therapeutics Registers 17.3 Million Shares for Resale

Outlook Therapeutics has registered 17.3 million shares for resale by various selling shareholders. These shares were issued as part of a private placement during the first quarter of fiscal year 2024. The filing aims to allow these shareholders to resell their restricted shares in …

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
scanx.trade Guidance Main company 🇺🇸 United States

Outlook Therapeutics files prospectus for 17.258M share offering

Outlook Therapeutics has filed a prospectus with the SEC for the sale of 17.258 million common shares by existing selling stockholders. The company will not receive any proceeds from this offering, which allows current shareholders to offload their stakes. This regulatory filing provides transparency …

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Guidance Main company 🇺🇸 United States

Outlook Therapeutics (NASDAQ: OTLK) files resale for 17.3M warrant-linked shares

Outlook Therapeutics has filed a Form S-3 registration statement for the resale of up to 17,258,065 shares of common stock, which are issuable upon the exercise of warrants from an April 23, 2026 financing. The company will not receive proceeds directly from the resale …

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Guidance Main company 🇺🇸 United States

Outlook Therapeutics (NASDAQ: OTLK) backs share increase, reverse split

Outlook Therapeutics (NASDAQ: OTLK) stockholders approved several key proposals at a special meeting on July 16, 2026. These include increasing the authorized common stock from 260 million to 600 million shares, approving the potential issuance of common shares underlying warrants from an April 2026 …

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
StocksToTrade Earnings Main company 🇺🇸 United States

OTLK Stock Tightens Range As Traders Watch Support

Outlook Therapeutics Inc. (OTLK) stock is experiencing a tightening trading range between the mid-$1.50s and high-$1.70s, signaling consolidation after recent volatility. The company, a clinical-stage biotech, faces significant financial challenges including low revenue, substantial losses, negative working capital, and ongoing dilution risk. Traders are …

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Guidance Main company 🇺🇸 United States

$Outlook Therapeutics (OTLK.US)$ looks like a cup and handle on the daily ans weekly chart. this should take off soon.

An analyst from the moomoo community, "Empchief," observes that Outlook Therapeutics (OTLK.US) displays a "cup and handle" pattern on its daily and weekly charts. This technical analysis suggests that the stock is poised for an upward movement in the near future.

OTLK main company
Sharemaestro market context Trend signal active 52 weeks -71.8% OTLK stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context